PMC:7116472 / 31378-32585 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"443","span":{"begin":142,"end":150},"obj":"Species"},{"id":"444","span":{"begin":156,"end":164},"obj":"Disease"},{"id":"445","span":{"begin":189,"end":198},"obj":"Disease"},{"id":"456","span":{"begin":537,"end":545},"obj":"Species"},{"id":"457","span":{"begin":996,"end":1004},"obj":"Species"},{"id":"458","span":{"begin":1143,"end":1151},"obj":"Chemical"},{"id":"459","span":{"begin":556,"end":565},"obj":"Disease"},{"id":"460","span":{"begin":608,"end":617},"obj":"Disease"},{"id":"461","span":{"begin":747,"end":756},"obj":"Disease"},{"id":"462","span":{"begin":758,"end":767},"obj":"Disease"},{"id":"463","span":{"begin":854,"end":863},"obj":"Disease"},{"id":"464","span":{"begin":926,"end":935},"obj":"Disease"},{"id":"465","span":{"begin":1054,"end":1059},"obj":"Disease"}],"attributes":[{"id":"A443","pred":"tao:has_database_id","subj":"443","obj":"Tax:9606"},{"id":"A444","pred":"tao:has_database_id","subj":"444","obj":"MESH:C000657245"},{"id":"A445","pred":"tao:has_database_id","subj":"445","obj":"MESH:D003643"},{"id":"A456","pred":"tao:has_database_id","subj":"456","obj":"Tax:9606"},{"id":"A457","pred":"tao:has_database_id","subj":"457","obj":"Tax:9606"},{"id":"A458","pred":"tao:has_database_id","subj":"458","obj":"MESH:D013256"},{"id":"A459","pred":"tao:has_database_id","subj":"459","obj":"MESH:D003643"},{"id":"A460","pred":"tao:has_database_id","subj":"460","obj":"MESH:D003643"},{"id":"A461","pred":"tao:has_database_id","subj":"461","obj":"MESH:D003643"},{"id":"A462","pred":"tao:has_database_id","subj":"462","obj":"MESH:D003643"},{"id":"A463","pred":"tao:has_database_id","subj":"463","obj":"MESH:D003643"},{"id":"A464","pred":"tao:has_database_id","subj":"464","obj":"MESH:D011014"},{"id":"A465","pred":"tao:has_database_id","subj":"465","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Conclusions and policy implications\nWe have derived and validated an easy-to-use eight variable score that enables accurate stratification of patients with covid-19 admitted to hospital by mortality risk at hospital presentation. Application within the validation cohorts showed this tool could guide clinician decisions, including treatment escalation.\nA key aim of risk stratification is to support clinical management decisions. Four risk classes were identified and showed similar adverse outcome rates across the validation cohort. Patients with a 4C Mortality Score falling within the low risk groups (mortality rate 1%) might be suitable for management in the community, while those within the intermediate risk group were at lower risk of mortality (mortality rate 10%; 22% of the cohort) and might be suitable for ward level monitoring. Similar mortality rates have been identified as an appropriate cut-off value in pneumonia risk stratification scores (CURB-65 and PSI).2122 Meanwhile patients with a score of 9 or higher were at high risk of death (around 40%), which could prompt aggressive treatment, including the initiation of steroids49 and early escalation to critical care if appropriate."}

{"project":"LitCovid-sentences","denotations":[{"id":"T195","span":{"begin":0,"end":35},"obj":"Sentence"},{"id":"T196","span":{"begin":36,"end":229},"obj":"Sentence"},{"id":"T197","span":{"begin":230,"end":353},"obj":"Sentence"},{"id":"T198","span":{"begin":354,"end":431},"obj":"Sentence"},{"id":"T199","span":{"begin":432,"end":536},"obj":"Sentence"},{"id":"T200","span":{"begin":537,"end":845},"obj":"Sentence"},{"id":"T201","span":{"begin":846,"end":1207},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Conclusions and policy implications\nWe have derived and validated an easy-to-use eight variable score that enables accurate stratification of patients with covid-19 admitted to hospital by mortality risk at hospital presentation. Application within the validation cohorts showed this tool could guide clinician decisions, including treatment escalation.\nA key aim of risk stratification is to support clinical management decisions. Four risk classes were identified and showed similar adverse outcome rates across the validation cohort. Patients with a 4C Mortality Score falling within the low risk groups (mortality rate 1%) might be suitable for management in the community, while those within the intermediate risk group were at lower risk of mortality (mortality rate 10%; 22% of the cohort) and might be suitable for ward level monitoring. Similar mortality rates have been identified as an appropriate cut-off value in pneumonia risk stratification scores (CURB-65 and PSI).2122 Meanwhile patients with a score of 9 or higher were at high risk of death (around 40%), which could prompt aggressive treatment, including the initiation of steroids49 and early escalation to critical care if appropriate."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T23","span":{"begin":926,"end":935},"obj":"Phenotype"}],"attributes":[{"id":"A23","pred":"hp_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"Conclusions and policy implications\nWe have derived and validated an easy-to-use eight variable score that enables accurate stratification of patients with covid-19 admitted to hospital by mortality risk at hospital presentation. Application within the validation cohorts showed this tool could guide clinician decisions, including treatment escalation.\nA key aim of risk stratification is to support clinical management decisions. Four risk classes were identified and showed similar adverse outcome rates across the validation cohort. Patients with a 4C Mortality Score falling within the low risk groups (mortality rate 1%) might be suitable for management in the community, while those within the intermediate risk group were at lower risk of mortality (mortality rate 10%; 22% of the cohort) and might be suitable for ward level monitoring. Similar mortality rates have been identified as an appropriate cut-off value in pneumonia risk stratification scores (CURB-65 and PSI).2122 Meanwhile patients with a score of 9 or higher were at high risk of death (around 40%), which could prompt aggressive treatment, including the initiation of steroids49 and early escalation to critical care if appropriate."}